PNPLA3 rs738409 C>G变异与非酒精性脂肪性肝病患者的肝脏相关结局相关
该研究对471例意大利NAFLD患者随访至少6个月(中位64.6个月),发现PNPLA3 rs738409 C>G变异与失代偿(HR 2.10)、肝细胞癌(HR 2.68)和肝脏相关死亡(HR 3.64)风险升高独立相关,且在F3纤维化或肝硬化亚组中一致。
要点
- PNPLA3 rs738409 C>G变异与NAFLD患者失代偿、HCC和肝脏相关死亡风险升高独立相关。
- 所有肝脏相关事件仅发生于F3纤维化或肝硬化患者。
- PNPLA3基因型与心血管事件、肝外肿瘤或总死亡率无关联。
核心结论
- 携带PNPLA3 rs738409 G>C变异的NAFLD患者肝脏相关事件和死亡风险更高。
研究设计与样本
- 前瞻性队列研究,纳入意大利某医院471例连续NAFLD患者(组织学诊断或临床诊断的代偿性NAFLD相关肝硬化),随访至少6个月,2004年3月至2018年12月。
主要发现
- 中位随访64.6个月(范围6.1-175个月)期间,记录26例失代偿、13例HCC和16例死亡(其中12例肝脏相关)。
- 所有肝脏相关事件(包括肝脏相关死亡)均发生于F3纤维化或肝硬化患者。
- PNPLA3 rs738409 GG、GT、TT基因型频率分别为31.8%、45.6%、22.6%。
临床怎么用
- 在NAFLD患者中检测PNPLA3 rs738409 C>G变异可能有助于识别肝脏相关事件和死亡风险更高的患者。
- 对于携带PNPLA3 rs738409 G>C变异的NAFLD患者,尤其是F3纤维化或肝硬化者,需关注失代偿、HCC和肝脏相关死亡风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with nonalcoholic fatty liver disease (NAFLD) have an increased risk for liver-related complications, such as decompensation, hepatocellular carcinoma (HCC), and death; the severity of liver fibrosis and metabolic comorbidities are the main risk factors. A single nucleotide polymorphism in patatin-like phospholipase domain-containing-3 (PNPLA3) gene is associated with higher prevalence of liver damage and HCC, but there are no data from prospective studies of outcomes of patients with this polymorphism. We investigated whether the common rs738409 variant in PNPLA3 gene associates with the occurrence of liver-related events and death in a large cohort of patients with NAFLD. METHODS: We followed 471 consecutive individuals at a hospital in Italy with a diagnosis of NAFLD based on histologic factors or a diagnosis of compensated NAFLD-related cirrhosis based on clinical factors for at least 6 months, from March 2004 through December 2018. We collected data on the occurrence of hepatic and extrahepatic outcomes, including decompensation and HCC, cardiovascular events and extrahepatic cancers, and overall and liver-related death. We detected the rs738409 G>C polymorphism in DNA from patient blood samples using the TaqMan assay. RESULTS: During a median follow-up time of 64.6 months (range 6.1-175 months) 26 cases of decompensation, 13 HCCs, and 16 deaths (12 liver-related) were recorded. All liver-related events, including liver-related death, occurred in patients with F3 fibrosis or cirrhosis. The prevalence of PNPLA3 rs738409 GG, GT, and TT genotypes was 31.8%, 45.6%, and 22.6%, respectively. After adjusting for clinical, metabolic, and histologic risk factors, PNPLA3 C>G variant was associated with a higher risk of decompensation (hazard ratio [HR], 2.10; 95% CI, 1.03-4.29; P = .04), HCC (HR, 2.68; 95% CI, 1.01-7.26; P = .04), and liver-related death (HR, 3.64; 95% CI, 1.18-11.2; P = .02) by multivariate Cox regression analysis. In the subgroup of 162 patients with F3 fibrosis or cirrhosis, we confirmed the independent association between the PNPLA3 variant and decompensation (HR, 2.00; 95% CI, 1.01-3.97; P = .04), HCC (HR, 2.66; 95% CI, 1.02-7.13; P = .04), and liver-related death (HR, 3.64, 95% CI, 1.18-11.2; P = .02). We found no association between PNPLA3 genotype and cardiovascular events, extrahepatic cancers, or overall mortality. CONCLUSIONS: Patients with NAFLD carrying PNPLA3 rs738409 G>C variant are at higher risk of liver-related events and death.
引用
- Grimaudo S, Pipitone RM, Pennisi G, et al. Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2019. PMID: 31419571. doi:10.1016/j.cgh.2019.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。